Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Vaccines|April 23, 2022
From Concept to Clinical Product: A Brief History of the Novel Shigella Invaplex Vaccine's Refinement and EvolutionK Ross Turbyfill, Kristen A Clarkson, Edwin V Oaks, et al.
Msphere|March 31, 2018
Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of Shigella Artificial InvaplexK Ross Turbyfill, Kristen A Clarkson, Anthony R Vortherms, et al.
Msphere|June 30, 2023
Development of the Shigella flexneri 2a, 3a, 6, and S. sonnei artificial Invaplex (InvaplexAR) vaccinesK Ross Turbyfill, Kristen A Clarkson, Edwin V Oaks, et al.
Vaccine|September 12, 2017
Improving chances for successful clinical outcomes with better preclinical modelsHeather Wenzel, Robert W Kaminski, Kristen A Clarkson, et al.
Msphere|July 14, 2021
Shigella-Specific Immune Profiles Induced after Parenteral Immunization or Oral Challenge with Either Shigella flexneri 2a or Shigella sonneiKristen A Clarkson, Chad K Porter, Kawsar R Talaat, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 10, 2019
Consensus Report on Shigella Controlled Human Infection Model: Immunological AssaysRobert W Kaminski, Marcela F Pasetti, Ana Older Aguilar, et al.
Current Topics in Microbiology and Immunology|May 26, 2022
Shigella-Controlled Human Infection Models: Current and Future PerspectivesKristen A Clarkson, Chad K Porter, Kawsar R Talaat, et al.
Msphere|September 15, 2025
Cross-comparison study of three ELISA methodologies to measure Shigella Sonnei O-antigen serum IgGPaul Stickings, Caroline Vipond, Peter Rigsby, et al.
Vaccine|September 4, 2023
GMP manufacture of Shigella flexneri 2a Artificial Invaplex (InvaplexAR) and evaluation in a Phase 1 Open-label, dose escalating study administered intranasally to healthy, adult volunteersChristopher Duplessis, Kristen A Clarkson, K Ross Turbyfill, et al.
Clinical and Vaccine Immunology : CVI|September 2, 2016
Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I StudyMark S Riddle, Robert W Kaminski, Claudio Di Paolo, et al.
Pageof 2